Investor Relations

About AVROBIO

Our mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing a program in Pompe disease. AVROBIO is powered by the plato® gene therapy platform, our foundation designed to scale gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.

Sign up for email alerts

Stock Chart


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations

Our News Latest press releases

Jul 08, 2020

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Read More

Jul 06, 2020

AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials

First patient dosed in AVROBIO’s global Phase 1/2 clinical trial of AVR-RD-02   for Gaucher disease type 1 Second patient dosed in investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 for cystinosis CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 6, 2020-- AVROBIO, Inc.

Read More

Jun 29, 2020

AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer

AVROBIO co-founder and veteran gene and cell therapy pioneer Kim Warren to retire July 31, 2020 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 29, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today

Read More

See All

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.